about
Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.Synthesis of α-aminoboronic acids.Sorafenib for the treatment of multiple myeloma.Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactionsPharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma.Progressive multifocal leukoencephalopathy during ixazomib-based chemotherapy.
P2860
Q33437811-250AB3BE-727B-4616-AAA5-53F131B42929Q38725603-82A871DD-B481-4DCF-A03E-7E9569BC5FFFQ38783055-5A7CDBA4-DB1C-4816-92C0-5887748A4FDEQ39234159-055ABC06-A88F-4C47-9DEF-FDCE9297D436Q41620033-F7147991-20A3-42A6-8F61-8195640A7694Q47784917-E26A45F4-07DC-49C4-9225-6F69A007A3A9Q52673077-2767FB2A-869B-47D6-87D3-E02E069DAAAB
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Ixazomib for the treatment of multiple myeloma.
@en
type
label
Ixazomib for the treatment of multiple myeloma.
@en
prefLabel
Ixazomib for the treatment of multiple myeloma.
@en
P2093
P2860
P1476
Ixazomib for the treatment of multiple myeloma
@en
P2093
Ernesto Vigna
Fortunato Morabito
Laura Corvatta
Lucio Morabito
Massimo Gentile
Silvia Gentili
P2860
P304
P356
10.1517/13543784.2015.1065250
P407
P577
2015-07-03T00:00:00Z